Enrollment closed to new patients in the Phase I trial investigating lirilumab in combination with ipilimumab
ASH 2014 : Lirilumab enhances Elotuzumab activity in preclinical models
Innate Pharma announces its financial calendar for 2015 as well as its participation in upcoming investor conferences
Financial information for the third quarter of 2014
IPH 4102 preclinical data published in “cancer research”
Innate Pharma presents two posters on proprietary BTG-ADC technology at the world ADC Summit
Initiation of a Phase I clinical trial of lirilumab in combination with elotuzumab
Third data and safety monitoring board meeting for EffiKIR trial recommends continuation as planned
First half of 2014: broadened clinical portfolio and strengthened cash position
Innate Pharma appoints Pierre Dodion as Chief Medical Officer and member of the Executive committee
